ID   MTA70_HUMAN             Reviewed;         580 AA.
AC   Q86U44; O14736; Q86V05; Q9HB32;
DT   25-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   25-JUL-2003, sequence version 2.
DT   10-MAY-2017, entry version 125.
DE   RecName: Full=N6-adenosine-methyltransferase 70 kDa subunit;
DE            Short=MT-A70;
DE            EC=2.1.1.62 {ECO:0000269|PubMed:27281194, ECO:0000269|PubMed:9409616};
DE   AltName: Full=Methyltransferase-like protein 3;
DE            Short=hMETTL3 {ECO:0000303|PubMed:27373337};
GN   Name=METTL3; Synonyms=MTA70;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), PROTEIN SEQUENCE OF
RP   48-56; 134-149 AND 509-522, FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND CATALYTIC ACTIVITY.
RX   PubMed=9409616;
RA   Bokar J.A., Shambaugh M.E., Polayes D., Matera A.G., Rottman F.M.;
RT   "Purification and cDNA cloning of the AdoMet-binding subunit of the
RT   human mRNA (N6-adenosine)-methyltransferase.";
RL   RNA 3:1233-1247(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43; SER-219 AND SER-243,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   FUNCTION.
RX   PubMed=22575960; DOI=10.1038/nature11112;
RA   Dominissini D., Moshitch-Moshkovitz S., Schwartz S., Salmon-Divon M.,
RA   Ungar L., Osenberg S., Cesarkas K., Jacob-Hirsch J., Amariglio N.,
RA   Kupiec M., Sorek R., Rechavi G.;
RT   "Topology of the human and mouse m6A RNA methylomes revealed by m6A-
RT   seq.";
RL   Nature 485:201-206(2012).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43; SER-219 AND THR-348,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   IDENTIFICATION IN THE WMM COMPLEX.
RX   PubMed=24407421; DOI=10.1038/cr.2014.3;
RA   Ping X.L., Sun B.F., Wang L., Xiao W., Yang X., Wang W.J.,
RA   Adhikari S., Shi Y., Lv Y., Chen Y.S., Zhao X., Li A., Yang Y.,
RA   Dahal U., Lou X.M., Liu X., Huang J., Yuan W.P., Zhu X.F., Cheng T.,
RA   Zhao Y.L., Wang X., Danielsen J.M., Liu F., Yang Y.G.;
RT   "Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine
RT   methyltransferase.";
RL   Cell Res. 24:177-189(2014).
RN   [15]
RP   IDENTIFICATION IN THE WMM COMPLEX.
RX   PubMed=24981863; DOI=10.1016/j.celrep.2014.05.048;
RA   Schwartz S., Mumbach M.R., Jovanovic M., Wang T., Maciag K.,
RA   Bushkin G.G., Mertins P., Ter-Ovanesyan D., Habib N., Cacchiarelli D.,
RA   Sanjana N.E., Freinkman E., Pacold M.E., Satija R., Mikkelsen T.S.,
RA   Hacohen N., Zhang F., Carr S.A., Lander E.S., Regev A.;
RT   "Perturbation of m6A writers reveals two distinct classes of mRNA
RT   methylation at internal and 5' sites.";
RL   Cell Rep. 8:284-296(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   FUNCTION.
RX   PubMed=24284625; DOI=10.1038/nature12730;
RA   Wang X., Lu Z., Gomez A., Hon G.C., Yue Y., Han D., Fu Y.,
RA   Parisien M., Dai Q., Jia G., Ren B., Pan T., He C.;
RT   "N-methyladenosine-dependent regulation of messenger RNA stability.";
RL   Nature 505:117-120(2014).
RN   [18]
RP   FUNCTION.
RX   PubMed=25719671; DOI=10.1038/nature14234;
RA   Liu N., Dai Q., Zheng G., He C., Parisien M., Pan T.;
RT   "N(6)-methyladenosine-dependent RNA structural switches regulate RNA-
RT   protein interactions.";
RL   Nature 518:560-564(2015).
RN   [19]
RP   FUNCTION, AND MUTAGENESIS OF 395-ASP--TRP-398.
RX   PubMed=25799998; DOI=10.1038/nature14281;
RA   Alarcon C.R., Lee H., Goodarzi H., Halberg N., Tavazoie S.F.;
RT   "N6-methyladenosine marks primary microRNAs for processing.";
RL   Nature 519:482-485(2015).
RN   [20]
RP   FUNCTION.
RX   PubMed=26321680; DOI=10.1016/j.cell.2015.08.011;
RA   Alarcon C.R., Goodarzi H., Lee H., Liu X., Tavazoie S., Tavazoie S.F.;
RT   "HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing
RT   events.";
RL   Cell 162:1299-1308(2015).
RN   [21]
RP   FUNCTION.
RX   PubMed=26593424; DOI=10.1016/j.cell.2015.10.012;
RA   Meyer K.D., Patil D.P., Zhou J., Zinoviev A., Skabkin M.A.,
RA   Elemento O., Pestova T.V., Qian S.B., Jaffrey S.R.;
RT   "5' UTR m(6)A promotes cap-independent translation.";
RL   Cell 163:999-1010(2015).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=26458103; DOI=10.1038/nature15377;
RA   Zhou J., Wan J., Gao X., Zhang X., Jaffrey S.R., Qian S.B.;
RT   "Dynamic m(6)A mRNA methylation directs translational control of heat
RT   shock response.";
RL   Nature 526:591-594(2015).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, INDUCTION, INTERACTION WITH NCBP1;
RP   EIF4E AND EIF3B, AND MUTAGENESIS OF 395-ASP--TRP-398.
RX   PubMed=27117702; DOI=10.1016/j.molcel.2016.03.021;
RA   Lin S., Choe J., Du P., Triboulet R., Gregory R.I.;
RT   "The m(6)A methyltransferase METTL3 promotes translation in human
RT   cancer cells.";
RL   Mol. Cell 62:335-345(2016).
RN   [24] {ECO:0000244|PDB:5K7M, ECO:0000244|PDB:5K7U, ECO:0000244|PDB:5K7W}
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 357-580 IN COMPLEX WITH
RP   METTL14 AND S-ADENOSYL-L-METHIONINE, FUNCTION, CATALYTIC ACTIVITY,
RP   SUBUNIT, MUTAGENESIS OF CYS-294; CYS-326; ASP-395; TRP-475 AND
RP   ASN-477, VARIANT CYS-406, AND CHARACTERIZATION OF VARIANT CYS-406.
RX   PubMed=27373337; DOI=10.1016/j.molcel.2016.05.041;
RA   Wang P., Doxtader K.A., Nam Y.;
RT   "Structural basis for cooperative function of Mettl3 and Mettl14
RT   methyltransferases.";
RL   Mol. Cell 63:306-317(2016).
RN   [25] {ECO:0000244|PDB:5IL0, ECO:0000244|PDB:5IL1, ECO:0000244|PDB:5IL2}
RP   X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 369-580 IN COMPLEX WITH
RP   METTL14 AND S-ADENOSYL-L-METHIONINE, FUNCTION, CATALYTIC ACTIVITY,
RP   SUBUNIT, DOMAIN, AND MUTAGENESIS OF ASP-377; ASP-395;
RP   462-GLN--GLY-479; GLU-532; ARG-536; HIS-538; ASN-539; ASN-549 AND
RP   GLN-550.
RX   PubMed=27281194; DOI=10.1038/nature18298;
RA   Wang X., Feng J., Xue Y., Guan Z., Zhang D., Liu Z., Gong Z., Wang Q.,
RA   Huang J., Tang C., Zou T., Yin P.;
RT   "Structural basis of N(6)-adenosine methylation by the METTL3-METTL14
RT   complex.";
RL   Nature 534:575-578(2016).
CC   -!- FUNCTION: The METTL3-METTL14 heterodimer forms a N6-
CC       methyltransferase complex that methylates adenosine residues of
CC       some RNAs and regulates the circadian clock, differentiation of
CC       embryonic stem cells and primary miRNA processing
CC       (PubMed:22575960, PubMed:24284625, PubMed:25719671,
CC       PubMed:25799998, PubMed:26321680, PubMed:26593424,
CC       PubMed:27373337, PubMed:27281194, PubMed:9409616). In the
CC       heterodimer formed with METTL14, METTL3 constitutes the catalytic
CC       core (PubMed:27373337, PubMed:27281194). N6-methyladenosine (m6A),
CC       which takes place at the 5'-[AG]GAC-3' consensus sites of some
CC       mRNAs, plays a role in the efficiency of mRNA splicing,
CC       processing, translation efficiency, editing and mRNA stability
CC       (PubMed:22575960, PubMed:24284625, PubMed:25719671,
CC       PubMed:25799998, PubMed:26321680, PubMed:26593424,
CC       PubMed:9409616). M6A regulates the length of the circadian clock:
CC       acts as an early pace-setter in the circadian loop by putting mRNA
CC       production on a fast-track for facilitating nuclear processing,
CC       thereby providing an early point of control in setting the
CC       dynamics of the feedback loop (By similarity). M6A also acts as a
CC       regulator of mRNA stability: in embryonic stem cells (ESCs), m6A
CC       methylation of mRNAs encoding key naive pluripotency-promoting
CC       transcripts results in transcript destabilization, promoting
CC       differentiation of ESCs (By similarity). M6A also takes place in
CC       other RNA molecules, such as primary miRNA (pri-miRNAs)
CC       (PubMed:25799998). METTL3 also mediates methylation of pri-miRNAs,
CC       marking them for recognition and processing by DGCR8
CC       (PubMed:25799998). Acts as a positive regulator of mRNA
CC       translation independently of the methyltransferase activity:
CC       promotes translation by interacting with the translation
CC       initiation machinery in the cytoplasm (PubMed:27117702). Its
CC       overexpression in a number of cancer cells suggests that it may
CC       participate to cancer cell proliferation by promoting mRNA
CC       translation (PubMed:27117702). {ECO:0000250|UniProtKB:Q8C3P7,
CC       ECO:0000269|PubMed:22575960, ECO:0000269|PubMed:24284625,
CC       ECO:0000269|PubMed:25719671, ECO:0000269|PubMed:25799998,
CC       ECO:0000269|PubMed:26321680, ECO:0000269|PubMed:26593424,
CC       ECO:0000269|PubMed:27117702, ECO:0000269|PubMed:27281194,
CC       ECO:0000269|PubMed:27373337, ECO:0000269|PubMed:9409616}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + m(7)G(5')pppAm = S-
CC       adenosyl-L-homocysteine + m(7)G(5')pppm(6)Am.
CC       {ECO:0000269|PubMed:27281194, ECO:0000269|PubMed:27373337,
CC       ECO:0000269|PubMed:9409616}.
CC   -!- ENZYME REGULATION: Methyltransferase activity is regulated by
CC       miRNAs via a sequence pairing mechanism.
CC       {ECO:0000250|UniProtKB:Q8C3P7}.
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with METTL14 to form an
CC       antiparallel heterodimer that constitutes an active
CC       methyltransferase (PubMed:27373337, PubMed:27281194). Component of
CC       the WMM complex, a N6-methyltransferase complex composed of WTAP,
CC       METTL3 and METTL14 (PubMed:24407421, PubMed:24981863). Interacts
CC       with NCBP1/CBP80 (PubMed:27117702). Interacts with EIF4E
CC       (PubMed:27117702). Interacts with EIF3B (PubMed:27117702).
CC       {ECO:0000269|PubMed:24407421, ECO:0000269|PubMed:24981863,
CC       ECO:0000269|PubMed:27117702, ECO:0000269|PubMed:27281194,
CC       ECO:0000269|PubMed:27373337}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:26458103,
CC       ECO:0000269|PubMed:27117702}. Nucleus speckle
CC       {ECO:0000269|PubMed:9409616}. Cytoplasm
CC       {ECO:0000269|PubMed:27117702}. Note=Colocalizes with speckles in
CC       interphase nuclei. Suggesting that it may be associated with
CC       nuclear pre-mRNA splicing components.
CC       {ECO:0000269|PubMed:9409616}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q86U44-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86U44-2; Sequence=VSP_007864, VSP_007865, VSP_007866;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed at low level. Expressed in
CC       spleen, thymus, prostate, testis, ovary, small intestine, colon
CC       and peripheral blood leukocytes. {ECO:0000269|PubMed:9409616}.
CC   -!- INDUCTION: Overexpressed in a number of cancer tissues, such as
CC       lung adenocarcinoma and colon adenocarcinoma (PubMed:27117702).
CC       {ECO:0000269|PubMed:27117702}.
CC   -!- DOMAIN: Gate loop 1 and gate loop 2 regions are adjacent to the S-
CC       adenosyl-L-homocysteine-binding site and display large
CC       conformational changes upon ligand-binding. They may play an
CC       important role in adenosine recognition. The interface loop
CC       contributes to the heterodimer interaction.
CC       {ECO:0000269|PubMed:27281194}.
CC   -!- SIMILARITY: Belongs to the MT-A70-like family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00489}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF014837; AAB71850.1; -; Genomic_DNA.
DR   EMBL; AF283991; AAG13956.1; -; Genomic_DNA.
DR   EMBL; AE000658; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX247964; CAD62303.1; -; mRNA.
DR   EMBL; BC003031; AAH03031.1; -; mRNA.
DR   EMBL; BC001650; AAH01650.1; -; mRNA.
DR   EMBL; BC052244; AAH52244.1; -; mRNA.
DR   CCDS; CCDS32044.1; -. [Q86U44-1]
DR   RefSeq; NP_062826.2; NM_019852.4. [Q86U44-1]
DR   UniGene; Hs.168799; -.
DR   PDB; 5IL0; X-ray; 1.88 A; A=369-580.
DR   PDB; 5IL1; X-ray; 1.71 A; A=369-580.
DR   PDB; 5IL2; X-ray; 1.61 A; A=369-580.
DR   PDB; 5K7M; X-ray; 1.65 A; A=357-580.
DR   PDB; 5K7U; X-ray; 1.70 A; A=357-580.
DR   PDB; 5K7W; X-ray; 1.65 A; A=357-580.
DR   PDB; 5L6D; X-ray; 1.85 A; A=354-580.
DR   PDB; 5L6E; X-ray; 1.90 A; A=354-580.
DR   PDB; 5TEY; X-ray; 1.80 A; A=1-580.
DR   PDBsum; 5IL0; -.
DR   PDBsum; 5IL1; -.
DR   PDBsum; 5IL2; -.
DR   PDBsum; 5K7M; -.
DR   PDBsum; 5K7U; -.
DR   PDBsum; 5K7W; -.
DR   PDBsum; 5L6D; -.
DR   PDBsum; 5L6E; -.
DR   PDBsum; 5TEY; -.
DR   ProteinModelPortal; Q86U44; -.
DR   SMR; Q86U44; -.
DR   BioGrid; 121139; 18.
DR   DIP; DIP-60727N; -.
DR   IntAct; Q86U44; 10.
DR   STRING; 9606.ENSP00000298717; -.
DR   iPTMnet; Q86U44; -.
DR   PhosphoSitePlus; Q86U44; -.
DR   BioMuta; METTL3; -.
DR   DMDM; 33301371; -.
DR   EPD; Q86U44; -.
DR   MaxQB; Q86U44; -.
DR   PaxDb; Q86U44; -.
DR   PeptideAtlas; Q86U44; -.
DR   PRIDE; Q86U44; -.
DR   DNASU; 56339; -.
DR   Ensembl; ENST00000298717; ENSP00000298717; ENSG00000165819. [Q86U44-1]
DR   GeneID; 56339; -.
DR   KEGG; hsa:56339; -.
DR   UCSC; uc001wbc.4; human. [Q86U44-1]
DR   CTD; 56339; -.
DR   DisGeNET; 56339; -.
DR   GeneCards; METTL3; -.
DR   HGNC; HGNC:17563; METTL3.
DR   MIM; 612472; gene.
DR   neXtProt; NX_Q86U44; -.
DR   OpenTargets; ENSG00000165819; -.
DR   PharmGKB; PA134955499; -.
DR   eggNOG; KOG2098; Eukaryota.
DR   eggNOG; COG4725; LUCA.
DR   GeneTree; ENSGT00550000075058; -.
DR   HOGENOM; HOG000012669; -.
DR   HOVERGEN; HBG052521; -.
DR   InParanoid; Q86U44; -.
DR   KO; K05925; -.
DR   OMA; HTKLWAM; -.
DR   OrthoDB; EOG091G07WA; -.
DR   PhylomeDB; Q86U44; -.
DR   TreeFam; TF323854; -.
DR   Reactome; R-HSA-72203; Processing of Capped Intron-Containing Pre-mRNA.
DR   GeneWiki; METTL3; -.
DR   GenomeRNAi; 56339; -.
DR   PRO; PR:Q86U44; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000165819; -.
DR   CleanEx; HS_METTL3; -.
DR   ExpressionAtlas; Q86U44; baseline and differential.
DR   Genevisible; Q86U44; HS.
DR   GO; GO:0036396; C:MIS complex; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016422; F:mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003729; F:mRNA binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0008173; F:RNA methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:1904047; F:S-adenosyl-L-methionine binding; IDA:UniProtKB.
DR   GO; GO:0006382; P:adenosine to inosine editing; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0061157; P:mRNA destabilization; ISS:UniProtKB.
DR   GO; GO:0080009; P:mRNA methylation; IDA:UniProtKB.
DR   GO; GO:0006397; P:mRNA processing; ISS:UniProtKB.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; IMP:UniProtKB.
DR   GO; GO:1903679; P:positive regulation of cap-independent translational initiation; IMP:UniProtKB.
DR   GO; GO:1990744; P:primary miRNA methylation; IDA:UniProtKB.
DR   GO; GO:0031053; P:primary miRNA processing; IDA:UniProtKB.
DR   GO; GO:0001510; P:RNA methylation; IMP:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; ISS:UniProtKB.
DR   InterPro; IPR025848; MT-A70.
DR   InterPro; IPR007757; MT-A70-like.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   Pfam; PF05063; MT-A70; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51143; MT_A70; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Biological rhythms;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Methyltransferase; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; RNA-binding; S-adenosyl-L-methionine; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    580       N6-adenosine-methyltransferase 70 kDa
FT                                subunit.
FT                                /FTId=PRO_0000207630.
FT   REGION      377    378       S-adenosyl-L-methionine binding.
FT                                {ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000244|PDB:5K7U,
FT                                ECO:0000244|PDB:5K7W,
FT                                ECO:0000269|PubMed:27281194,
FT                                ECO:0000269|PubMed:27373337}.
FT   REGION      396    410       Gate loop 1.
FT                                {ECO:0000303|PubMed:27281194}.
FT   REGION      450    454       Interaction with METTL14.
FT                                {ECO:0000244|PDB:5IL0,
FT                                ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000269|PubMed:27281194}.
FT   REGION      462    479       Interphase loop.
FT                                {ECO:0000303|PubMed:27281194}.
FT   REGION      464    480       Interaction with METTL14.
FT                                {ECO:0000244|PDB:5IL0,
FT                                ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000269|PubMed:27281194}.
FT   REGION      465    478       Positively charged region required for
FT                                RNA-binding.
FT                                {ECO:0000269|PubMed:27281194}.
FT   REGION      507    515       Gate loop 2.
FT                                {ECO:0000303|PubMed:27281194}.
FT   REGION      536    539       S-adenosyl-L-methionine binding.
FT                                {ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000244|PDB:5K7U,
FT                                ECO:0000244|PDB:5K7W,
FT                                ECO:0000269|PubMed:27281194,
FT                                ECO:0000269|PubMed:27373337}.
FT   REGION      549    550       S-adenosyl-L-methionine binding.
FT                                {ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000244|PDB:5K7U,
FT                                ECO:0000244|PDB:5K7W,
FT                                ECO:0000269|PubMed:27281194,
FT                                ECO:0000269|PubMed:27373337}.
FT   BINDING     395    395       S-adenosyl-L-methionine.
FT                                {ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000244|PDB:5K7U,
FT                                ECO:0000244|PDB:5K7W,
FT                                ECO:0000269|PubMed:27281194,
FT                                ECO:0000269|PubMed:27373337}.
FT   BINDING     438    438       Interaction with METTL14.
FT                                {ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000269|PubMed:27281194}.
FT   BINDING     441    441       Interaction with METTL14.
FT                                {ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000269|PubMed:27281194}.
FT   BINDING     513    513       S-adenosyl-L-methionine.
FT                                {ECO:0000244|PDB:5IL1,
FT                                ECO:0000244|PDB:5IL2,
FT                                ECO:0000244|PDB:5K7U,
FT                                ECO:0000244|PDB:5K7W,
FT                                ECO:0000269|PubMed:27281194,
FT                                ECO:0000269|PubMed:27373337}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      43     43       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     219    219       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     243    243       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     348    348       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    284       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_007864.
FT   VAR_SEQ     486    505       GVKGNPQGFNQGLDCDVIVA -> SSSGAQFNRWSTKKNHL
FT                                ISY (in isoform 2). {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_007865.
FT   VAR_SEQ     506    580       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_007866.
FT   VARIANT     406    406       Y -> C (found in patients with large
FT                                intestine cancer; unknown pathological
FT                                significance; does not affect interaction
FT                                with METTL14; abolished RNA
FT                                methyltransferase activity in vitro).
FT                                {ECO:0000269|PubMed:27373337}.
FT                                /FTId=VAR_076859.
FT   MUTAGEN     294    294       C->A: Abolishes methyltransferase
FT                                activity. {ECO:0000269|PubMed:27373337}.
FT   MUTAGEN     326    326       C->A: Abolishes methyltransferase
FT                                activity. {ECO:0000269|PubMed:27373337}.
FT   MUTAGEN     377    377       D->A: Abolishes methyltransferase
FT                                activity. {ECO:0000269|PubMed:27281194}.
FT   MUTAGEN     395    398       DPPW->APPA: Loss of function. Abolishes
FT                                ability to regulate primary miRNA
FT                                processing. Does not affect ability to
FT                                promote mRNA translation.
FT                                {ECO:0000269|PubMed:25799998,
FT                                ECO:0000269|PubMed:27117702}.
FT   MUTAGEN     395    395       D->A: Abolishes methyltransferase
FT                                activity. {ECO:0000269|PubMed:27281194,
FT                                ECO:0000269|PubMed:27373337}.
FT   MUTAGEN     462    479       QLQRIIRTGRTGHWLNHG->AAAAAA: Impaired RNA-
FT                                binding and methyltransferase activities.
FT                                {ECO:0000269|PubMed:27281194}.
FT   MUTAGEN     475    475       W->A: Decreased methyltransferase
FT                                activity. {ECO:0000269|PubMed:27373337}.
FT   MUTAGEN     477    477       N->A: Decreased methyltransferase
FT                                activity. {ECO:0000269|PubMed:27373337}.
FT   MUTAGEN     532    532       E->A: Abolishes methyltransferase
FT                                activity. {ECO:0000269|PubMed:27281194}.
FT   MUTAGEN     536    536       R->A: Slight reduction in
FT                                methyltransferase activity.
FT                                {ECO:0000269|PubMed:27281194}.
FT   MUTAGEN     538    538       H->A: Slight reduction in
FT                                methyltransferase activity.
FT                                {ECO:0000269|PubMed:27281194}.
FT   MUTAGEN     539    539       N->A: Abolishes methyltransferase
FT                                activity. {ECO:0000269|PubMed:27281194}.
FT   MUTAGEN     549    549       N->A: Slight reduction in
FT                                methyltransferase activity.
FT                                {ECO:0000269|PubMed:27281194}.
FT   MUTAGEN     550    550       Q->A: Slight reduction in
FT                                methyltransferase activity.
FT                                {ECO:0000269|PubMed:27281194}.
FT   CONFLICT    251    251       N -> I (in Ref. 1; AAB71850).
FT                                {ECO:0000305}.
FT   CONFLICT    263    264       KF -> I (in Ref. 1; AAB71850).
FT                                {ECO:0000305}.
FT   CONFLICT    382    382       D -> V (in Ref. 1; AAB71850).
FT                                {ECO:0000305}.
FT   CONFLICT    568    568       R -> K (in Ref. 4; AAH52244).
FT                                {ECO:0000305}.
FT   STRAND      372    376       {ECO:0000244|PDB:5IL2}.
FT   TURN        378    380       {ECO:0000244|PDB:5IL2}.
FT   HELIX       383    386       {ECO:0000244|PDB:5IL2}.
FT   STRAND      390    394       {ECO:0000244|PDB:5IL2}.
FT   HELIX       411    416       {ECO:0000244|PDB:5IL2}.
FT   HELIX       419    422       {ECO:0000244|PDB:5IL2}.
FT   STRAND      424    432       {ECO:0000244|PDB:5IL2}.
FT   HELIX       436    446       {ECO:0000244|PDB:5IL2}.
FT   STRAND      450    460       {ECO:0000244|PDB:5IL2}.
FT   STRAND      464    466       {ECO:0000244|PDB:5IL2}.
FT   STRAND      473    477       {ECO:0000244|PDB:5IL2}.
FT   STRAND      480    489       {ECO:0000244|PDB:5IL2}.
FT   STRAND      498    506       {ECO:0000244|PDB:5IL2}.
FT   STRAND      510    512       {ECO:0000244|PDB:5IL2}.
FT   HELIX       516    524       {ECO:0000244|PDB:5IL2}.
FT   STRAND      530    534       {ECO:0000244|PDB:5IL2}.
FT   HELIX       537    539       {ECO:0000244|PDB:5IL2}.
FT   STRAND      544    548       {ECO:0000244|PDB:5IL2}.
FT   STRAND      553    555       {ECO:0000244|PDB:5IL2}.
FT   HELIX       559    568       {ECO:0000244|PDB:5IL2}.
SQ   SEQUENCE   580 AA;  64474 MW;  63A7F10195A3C6AC CRC64;
     MSDTWSSIQA HKKQLDSLRE RLQRRRKQDS GHLDLRNPEA ALSPTFRSDS PVPTAPTSGG
     PKPSTASAVP ELATDPELEK KLLHHLSDLA LTLPTDAVSI CLAISTPDAP ATQDGVESLL
     QKFAAQELIE VKRGLLQDDA HPTLVTYADH SKLSAMMGAV AEKKGPGEVA GTVTGQKRRA
     EQDSTTVAAF ASSLVSGLNS SASEPAKEPA KKSRKHAASD VDLEIESLLN QQSTKEQQSK
     KVSQEILELL NTTTAKEQSI VEKFRSRGRA QVQEFCDYGT KEECMKASDA DRPCRKLHFR
     RIINKHTDES LGDCSFLNTC FHMDTCKYVH YEIDACMDSE APGSKDHTPS QELALTQSVG
     GDSSADRLFP PQWICCDIRY LDVSILGKFA VVMADPPWDI HMELPYGTLT DDEMRRLNIP
     VLQDDGFLFL WVTGRAMELG RECLNLWGYE RVDEIIWVKT NQLQRIIRTG RTGHWLNHGK
     EHCLVGVKGN PQGFNQGLDC DVIVAEVRST SHKPDEIYGM IERLSPGTRK IELFGRPHNV
     QPNWITLGNQ LDGIHLLDPD VVARFKQRYP DGIISKPKNL
//
